''On standalone basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of RPG Life Sciences has increased 12.37% to Rs 172.71 crore. Operating profit margin has jumped from 24.66% to 28.46%, leading to 29.71% rise in operating profit to Rs 49.16 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 16.92% to 17.81%. Purchase of finished goods cost rose from 11.23% to 13.39%. Employee cost decreased from 22.94% to 16.94%. Other expenses fell from 23.11% to 22.85%.
Other income up 72.40% to Rs 3.31 crore. PBIDT rose 31.77% to Rs 52.47 crore. Provision for interest fell 14.29% to Rs 0.12 crore.
PBDT rose 31.93% to Rs 52.35 crore. Provision for depreciation rose 31.88% to Rs 5.46 crore.
Profit before tax grew 31.94% to ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|